Wilmington Savings Fund Society FSB acquired a new stake in shares of Absci Co. (NASDAQ:ABSI - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 189,522 shares of the company's stock, valued at approximately $724,000. Wilmington Savings Fund Society FSB owned approximately 0.17% of Absci as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in Absci by 379.6% during the third quarter. Barclays PLC now owns 131,504 shares of the company's stock valued at $503,000 after buying an additional 104,083 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Absci by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,933,593 shares of the company's stock valued at $7,388,000 after acquiring an additional 123,896 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Absci by 44.8% in the 3rd quarter. Wellington Management Group LLP now owns 348,854 shares of the company's stock worth $1,333,000 after purchasing an additional 107,980 shares during the last quarter. Polar Asset Management Partners Inc. bought a new stake in Absci during the third quarter worth approximately $523,000. Finally, Fred Alger Management LLC boosted its position in Absci by 4.3% during the third quarter. Fred Alger Management LLC now owns 7,566,618 shares of the company's stock worth $28,904,000 after purchasing an additional 309,843 shares during the period. 52.05% of the stock is currently owned by institutional investors and hedge funds.
Absci Stock Performance
Shares of Absci stock traded up $0.14 during midday trading on Monday, hitting $3.83. The company had a trading volume of 2,541,344 shares, compared to its average volume of 1,408,700. The stock has a market cap of $439.90 million, a PE ratio of -4.32 and a beta of 2.02. Absci Co. has a 1-year low of $2.45 and a 1-year high of $6.72. The business's 50 day simple moving average is $3.60 and its two-hundred day simple moving average is $3.81. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63.
Absci (NASDAQ:ABSI - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.77 million. During the same quarter in the prior year, the business earned ($0.24) earnings per share. As a group, equities analysts predict that Absci Co. will post -0.9 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on ABSI shares. Guggenheim restated a "buy" rating and issued a $10.00 price objective on shares of Absci in a research note on Tuesday, December 3rd. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Absci in a research report on Friday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $8.67.
View Our Latest Research Report on ABSI
About Absci
(
Free Report)
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Further Reading
Before you consider Absci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.
While Absci currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.